Mulpleta, Lusutrombopag Shionogi, Mulpleo (lusutrombopag) is a small molecule pharmaceutical. Lusutrombopag was first approved as Mulpleta on 2018-07-31. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. The pharmaceutical is active against thrombopoietin receptor. Mulpleta's patents are valid until 2031-09-29 (FDA).
|Trade Name||Lusutrombopag Shionogi, Mulpleo|
|Drug Class||Thrombopoetin agonists|